The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Approaching the treatment of a patient with DLBCL who has relapsed following Glofit-GemOx
Gareth Gregory, MBBS, PhD, FRACP, FRCPA, Fiona Stanley Hospital & Monash University, Perth, Australia, comments on the management of patients with diffuse large B-cell lymphoma (DLBCL) who relapse after the combination of glofitamab with gemcitabine and oxaliplatin (Glofit-GemOx). Dr Gregory emphasizes that subsequent therapy should be guided by the patient’s prior treatment history and performance status. As some patients may not receive Glofit-GemOx until the third-line setting, Dr Gregory notes that available treatment options at relapse are limited in this scenario. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So now that we will have the combination of Glofitamab and GemOx becoming available with registration internationally in many jurisdictions, the question is how do we best sequence whether it is in the second line. In this study it was both the second line and third line plus and the benefit of the risk of the investigational product Glofitamab was demonstrated in both subgroups...
So now that we will have the combination of Glofitamab and GemOx becoming available with registration internationally in many jurisdictions, the question is how do we best sequence whether it is in the second line. In this study it was both the second line and third line plus and the benefit of the risk of the investigational product Glofitamab was demonstrated in both subgroups. Realistically now we’ll be approaching patients with subsequent therapies according to which line they’re having it. For instance if they’ve already seen R-CHOP or Polatuzumab-containing R-CHP in the front line, if they’re seeing CAR-T in the second line if they progress within 12 months, that’s where Glofitamab-GemOx won’t come in until the third line and therefore patients will already have been through CAR-T and bispecifics and we’re left with a smaller pool of investigational therapies or directed therapies to go for. So what therapies we follow in with after Glofitamab-GemOx will largely be defined by prior therapies and the patient’s performance status.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
